Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2014 | Pages:
98 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Postherpetic Neuralgia - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Postherpetic Neuralgia - Pipeline Review, H2 2014', provides an overview of the Postherpetic Neuralgia's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Postherpetic Neuralgia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Postherpetic Neuralgia and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Postherpetic Neuralgia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Postherpetic Neuralgia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Postherpetic Neuralgia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Postherpetic Neuralgia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Postherpetic Neuralgia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Postherpetic Neuralgia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Postherpetic Neuralgia Overview 8 Therapeutics Development 9 Pipeline Products for Postherpetic Neuralgia - Overview 9 Pipeline Products for Postherpetic Neuralgia - Comparative Analysis 10 Postherpetic Neuralgia - Therapeutics under Development by Companies 11 Postherpetic Neuralgia - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Postherpetic Neuralgia - Products under Development by Companies 17 Postherpetic Neuralgia - Companies Involved in Therapeutics Development 18 Bristol-Myers Squibb Company 18 Allergan, Inc. 19 Acorda Therapeutics, Inc. 20 Astellas Pharma Inc. 21 Daewoong Pharmaceutical Co., Ltd. 22 Pfizer Inc. 23 Purdue Pharma L.P. 24 Teva Pharmaceutical Industries Limited 25 Impax Laboratories, Inc. 26 Nuvo Research Inc. 27 Arcion Therapeutics, Inc. 28 NeurAxon, Inc. 29 Winston Pharmaceuticals, Inc. 30 Spinifex Pharmaceuticals Pty Limited 31 Relmada Therapeutics, Inc. 32 Aestus Therapeutics, Inc. 33 Convergence Pharmaceuticals Ltd. 34 Immune Pharmaceuticals, Inc. 35 Scilex Pharmaceuticals, Inc. 36 Postherpetic Neuralgia - Therapeutics Assessment 37 Assessment by Monotherapy Products 37 Assessment by Combination Products 38 Assessment by Target 39 Assessment by Mechanism of Action 42 Assessment by Route of Administration 45 Assessment by Molecule Type 47 Drug Profiles 49 (amitriptyline + ketamine) - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 pregabalin CR - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 bupivacaine - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 NP-1998 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 NXN-462 - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 TV-45070 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 zucapsaicin - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 senrebotase - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 DWP-05195 - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 EMA-401 - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 BMS-954561 - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 Atx08-001 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 CNV-2197944 - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 ASP-8477 - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 V-116517 - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 Flexicaine - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 lidocaine - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 lidocaine - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 mepivacaine hydrochloride - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 (naltrexone + clonidine) - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 PRTT-200 - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 Postherpetic Neuralgia - Recent Pipeline Updates 77 Postherpetic Neuralgia - Dormant Projects 87 Postherpetic Neuralgia - Discontinued Products 88 Postherpetic Neuralgia - Product Development Milestones 89 Featured News & Press Releases 89 Aug 12, 2014: Pfizer Reports Top-line Results from Postherpetic Neuralgia and Painful Diabetic Peripheral Neuropathy Lyrica Studies Conducted in China 89 Aug 11, 2014: Scilex Pharmaceuticals Completes Trial Enrollment for Ztlido 89 Jul 14, 2014: SCILEX Pharmaceuticals Commences Dermal Safety Studies of Ztlido 90 May 19, 2014: Scilex Pharmaceuticals Initiates Pivotal Pharmacokinetic Study for Ztilido 90 Mar 24, 2014: Scilex Pharmaceuticals Announces Filing of Investigational New Drug Application for Ztilido 91 Feb 21, 2014: Endo Announces Resolution of Government Investigation 91 Feb 21, 2014: Endo Pharmaceuticals and Endo Health Solutions to Pay $192.7 Million to Resolve Criminal and Civil Liability Relating to Marketing of Prescription Drug Lidoderm for Unapproved Uses 92 Feb 05, 2014: Spinifex Pharmaceuticals' Phase 2 Results Published in The Lancet Show EMA401 to be Effective in Reducing Pain in Postherpetic Neuralgia 94 Jul 08, 2013: Convergence Pharmaceuticals Announces Start of Phase II Study for Cav2.2 Selective Blocker, CNV2197944 in Pain Associated with Post-Herpetic Neuralgia 95 Jun 28, 2013: Two New Formulations of E Keppra Developed Dry Syrup Obtains Approval; Application Filed for Injectable Formulation 96 Appendix 97 Methodology 97 Coverage 97 Secondary Research 97 Primary Research 97 Expert Panel Validation 97 Contact Us 98 Disclaimer 98
List of Tables Number of Products under Development for Postherpetic Neuralgia, H2 2014 9 Number of Products under Development for Postherpetic Neuralgia - Comparative Analysis, H2 2014 10 Number of Products under Development by Companies, H2 2014 12 Number of Products under Development by Companies, H2 2014 (Contd..1) 13 Comparative Analysis by Late Stage Development, H2 2014 14 Comparative Analysis by Clinical Stage Development, H2 2014 15 Comparative Analysis by Early Stage Development, H2 2014 16 Products under Development by Companies, H2 2014 17 Postherpetic Neuralgia - Pipeline by Bristol-Myers Squibb Company, H2 2014 18 Postherpetic Neuralgia - Pipeline by Allergan, Inc., H2 2014 19 Postherpetic Neuralgia - Pipeline by Acorda Therapeutics, Inc., H2 2014 20 Postherpetic Neuralgia - Pipeline by Astellas Pharma Inc., H2 2014 21 Postherpetic Neuralgia - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2014 22 Postherpetic Neuralgia - Pipeline by Pfizer Inc., H2 2014 23 Postherpetic Neuralgia - Pipeline by Purdue Pharma L.P., H2 2014 24 Postherpetic Neuralgia - Pipeline by Teva Pharmaceutical Industries Limited, H2 2014 25 Postherpetic Neuralgia - Pipeline by Impax Laboratories, Inc., H2 2014 26 Postherpetic Neuralgia - Pipeline by Nuvo Research Inc., H2 2014 27 Postherpetic Neuralgia - Pipeline by Arcion Therapeutics, Inc., H2 2014 28 Postherpetic Neuralgia - Pipeline by NeurAxon, Inc., H2 2014 29 Postherpetic Neuralgia - Pipeline by Winston Pharmaceuticals, Inc., H2 2014 30 Postherpetic Neuralgia - Pipeline by Spinifex Pharmaceuticals Pty Limited, H2 2014 31 Postherpetic Neuralgia - Pipeline by Relmada Therapeutics, Inc., H2 2014 32 Postherpetic Neuralgia - Pipeline by Aestus Therapeutics, Inc., H2 2014 33 Postherpetic Neuralgia - Pipeline by Convergence Pharmaceuticals Ltd., H2 2014 34 Postherpetic Neuralgia - Pipeline by Immune Pharmaceuticals, Inc., H2 2014 35 Postherpetic Neuralgia - Pipeline by Scilex Pharmaceuticals, Inc., H2 2014 36 Assessment by Monotherapy Products, H2 2014 37 Assessment by Combination Products, H2 2014 38 Number of Products by Stage and Target, H2 2014 41 Number of Products by Stage and Mechanism of Action, H2 2014 44 Number of Products by Stage and Route of Administration, H2 2014 46 Number of Products by Stage and Molecule Type, H2 2014 48 Postherpetic Neuralgia Therapeutics - Recent Pipeline Updates, H2 2014 77 Postherpetic Neuralgia - Dormant Projects, H2 2014 87 Postherpetic Neuralgia - Discontinued Products, H2 2014 88
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
